Changes in mucosal status, microcirculation parameters, and immunological parameters in response to combined non-hormonal therapy for vulvovaginal atrophy: A prospective study

Cover Page

Cite item

Full Text

Abstract

Background. The relevance of age-related diseases stems from the ongoing aging of the population; in Russia, the share of women over 45 is 57.3%. The typical presentation of age-related changes includes vulvovaginal atrophy (VVA), which has extensive symptoms. The intimate nature of the problem often prevents women from discussing it openly. Hormone therapy is a traditional treatment option for VVA and its symptoms; however, it has some limitations.

Aim. To compare the clinical effect of a combination therapy with hyaluronic acid and a phytoestrogen complex, as well as antimicrobial peptides and cytokines, with traditional local hormonal therapy.

Materials and methods. The study included 68 female patients with VVA symptoms and 72 females without VVA manifestations. VVA patients were divided into two groups: in the test group, women received combined trophic therapy, and in the control group, subjects received traditional local hormone therapy. To assess the effectiveness of treatment at baseline and at 1 and 3 months after the end of therapy, analyses of cytological tests, ultrasound examinations, and enzyme immunoassays were performed, and a vaginal health index was calculated.

Results. The overall treatment effectiveness in the test group was not inferior to that of local hormone therapy, as indicated by laboratory and instrumental parameters. Two therapeutic approaches had different effects on immunological parameters: in the test group, the level of interleukin-6 in vaginal swabs of patients receiving a combination of a protein-peptide complex, cytokines, hyaluronic acid, and phytoestrogens significantly decreased and differed significantly from that in the comparison group.

Conclusion. The described non-hormonal approach to the treatment of VVA manifestations has significantly fewer limitations for use than hormonal agents, a pronounced positive effect on local immunity, and is well tolerated by patients. Therefore, the combination of hyaluronic acid and a phytoestrogen complex, as well as antimicrobial peptides and cytokines, is effective and safe and can become an alternative to traditional hormonal treatment.

About the authors

Tatiana M. Motovilova

Privolzhsky Research Medical University; Clinic of Modern Technologies “Sadko”

Author for correspondence.
Email: tmshka@mail.ru
ORCID iD: 0000-0002-3795-2852

D. Sci. (Med.)

Russian Federation, Nizhny Novgorod; Nizhny Novgorod

Liya Z. Sirotina

Privolzhsky Research Medical University; Clinic of Modern Technologies “Sadko”

Email: tmshka@mail.ru
ORCID iD: 0000-0001-5081-1053

Assistant

Russian Federation, Nizhny Novgorod; Nizhny Novgorod

Irina V. Martiantseva

Clinic of Modern Technologies “Sadko”

Email: tmshka@mail.ru
ORCID iD: 0000-0003-4909-5250

Laboratory Head

Russian Federation, Nizhny Novgorod

Oksana I. Trifonova

Clinic of Modern Technologies “Sadko”

Email: tmshka@mail.ru
ORCID iD: 0009-0005-6976-429X

Ultrasound Diagnostic Doctor

Russian Federation, Nizhny Novgorod

Irina A. Kruglova

City Clinical Hospital No. 35

Email: tmshka@mail.ru
ORCID iD: 0000-0001-7955-349X

Clinical Laboratory Diagnostics Physician

Russian Federation, Nizhny Novgorod

Kseniia V. Kazakova

Privolzhsky Research Medical University

Email: tmshka@mail.ru
ORCID iD: 0009-0002-1849-5817

Medical Resident

Russian Federation, Nizhny Novgorod

Anastasiya D. Varnavskaya

Privolzhsky Research Medical University

Email: tmshka@mail.ru
ORCID iD: 0009-0009-8767-4414

Medical Resident

Russian Federation, Nizhny Novgorod

Varvara A. Kosareva

Privolzhsky Research Medical University

Email: tmshka@mail.ru
ORCID iD: 0009-0007-8695-1008

Student

Russian Federation, Nizhny Novgorod

References

  1. Carlson K, Nguyen H. Genitourinary syndrome of menopause. StatPearls. Treasure Island (FL): StatPearls Publishing, 2025.
  2. Nappi RE, Seracchioli R, Salvatore S, et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;35(5):453-9. doi: 10.1080/09513590.2018.1563883
  3. Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-8. doi: 10.1097/GME.0000000000000329
  4. Оразов М.Р., Силантьева Е.С., Радзинский В.Е., и др. Факторы риска развития и механизмы патогенеза генитоуринарного менопаузального синдрома. Российский вестник акушера-гинеколога. 2023;23(4):44-9 [Orazov MR, Silantyeva ES, Radzinskii VE, et al. Risk factors and pathogenetic mechanisms of genitourinary menopausal syndrome. Russ Bull Obstet Gynecol. 2023;23(4):44-9 (in Russian)]. doi: 10.21508/1027-4065-2023-23-4-44-49
  5. Зиганшина Л.З., Муслимова С.Ю., Сахаутдинова И.В., Зулкарнеева Э.М. Симптомы и клиника постменопаузальной вульвовагинальной атрофии в различные стадии постменопаузы. Гинекология. 2023;25(2):153-7 [Ziganshina LZ, Muslimova SY, Sakhautdinova IV, Zulkarneeva EM. Symptoms and clinic of postmenopausal vulvovaginal atrophy in different stages of postmenopause: A cross sectional study. Gynecology. 2023;25(2):153-7 (in Russian)]. doi: 10.26442/20795696.2023.2.202132
  6. Andreeva EN, Sheremetyeva EV. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women. Probl Endokrinol (Mosk). 2022;68(6):157-63. doi: 10.14341/probl13198
  7. Nappi RE, Cucinella L, Martini E, Cassani C. The role of hormone therapy in urogenital health after menopause. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101595. doi: 10.1016/j.beem.2021.101595
  8. Villa P, Cipolla C, D'Ippolito S, et al. The interplay between immune system and microbiota in gynecological diseases: a narrative review. Eur Rev Med Pharmacol Sci. 2020;24(10):5676-90. doi: 10.26355/eurrev_202005_21359
  9. Rodriguez-Garcia M, Patel MV, Shen Z, Wira CR. The impact of aging on innate and adaptive immunity in the human female genital tract. Aging Cell. 2021;20(5):e13361. doi: 10.1111/acel.13361
  10. Madanchi H, Shoushtari M, Kashani HH, Sardari S. Antimicrobial peptides of the vaginal innate immunity and their role in the fight against sexually transmitted diseases. New Microbes New Infect. 2019;34:100627. doi: 10.1016/j.nmni.2019.100627
  11. Byrne EH, Song H, Srinivasan S, et al. Association between vaginal microbiota and vaginal inflammatory immune markers in postmenopausal women. Menopause. 2024;31(7):575-81. doi: 10.1097/GME.0000000000002362
  12. Довлетханова Э.Р. Диагностика ВПЧ-ассоциированных заболеваний шейки матки у женщин в постменопаузе. Проблемы и пути решения. Фарматека. 2022;29(6):71-5. [Dovletkhanova ER. Diagnosis of HPV-associated cervical diseases in postmenopausal women. Problems and solutions. Farmateka. 2022;29(6):71-5 (in Russian)]. doi: 10.18565/pharmateca.2022.6.71-75
  13. Jais M, Younes N, Chapman S, et al. Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition. Am J Obstet Gynecol. 2016;215(3):324.e1-324.e10. doi: 10.1016/j.ajog.2016.03.041
  14. Оразов М.Р., Демяшкин Г.А., Токтар Л.Р. Ремоделирующая лазерная терапия влагалища при генитоуринарном менопаузальном синдроме. Хирургическая практика. 2018;(1):22-37 [Orazov MR, Demyashkin GA, Toktar LR. Remodeling laser therapy of the vagina in genitourinary menopausal syndrome. Surg Pract. 2018;(1):22-37 (in Russian)]. doi: 10.17238/issn2223-2427.2018.1.22-37
  15. Оразов М.Р., Силантьева Е.С., Радзинский В.Е., и др. Эффективность лазерной ремоделирующей терапии при генитоуринарном менопаузальном синдроме. Гинекология. 2022;24(6):465-70 [Orazov MR, Silantyeva ES, Radzinsky VE, et al. Efficacy of laser remodeling in the genitourinary syndrome of menopause: A review. Gynecology. 2022;24(6):465-70 (in Russian)]. doi: 10.26442/20795696.2022.6.201897
  16. Stephens P, Genever P. Non-epithelial oral mucosal progenitor cell populations. Oral Dis. 2007;13(1):1-10. doi: 10.1111/j.1601-0825.2006.01314.x
  17. Parsonage G, Filer AD, Haworth O, et al. A stromal address code defined by fibroblasts. Trends Immunol. 2005;26(3):150-6. doi: 10.1016/j.it.2004.11.014
  18. Agrawal S, LaPier Z, Nagpal S, et al. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause. 2024;31(9):750-5. doi: 10.1097/GME.0000000000002390
  19. Менопауза и климактерическое состояние у женщины. Клинические рекомендации Министерства здравоохранения Российской Федерации. 2025. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/117_3. Ссылка активна на 14.03.2025 [Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii Ministerstva zdravookhraneniia Rossiiskoi Federatsii. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/117_3. Accessed: 14.03.2025 (in Russian)].
  20. Мотовилова Т.Б., Сиротина Л.З., Трифонова О.Ю., и др. Негормональные терапевтические возможности при вульвовагинальной атрофии. Разбор клинических случаев. Гинекология. 2025;27(1):87-91 [Motovilova TB, Sirotina LZ, Trifonova OI, et al. Non-hormonal therapies for vulvovaginal atrophy: Clinical cases. Gynecology. 2025;27(1):87-91 (in Russian)]. doi: 10.26442/20795696.2025.1.203132
  21. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины [117_2]. 2024. Режим доступа: https://cr.minzdrav.gov.ru/archive. Ссылка активна на 20.08.2024 [Ministerstvo zdravookhraneniia Rossiiskoi Federatsii. Klinicheskie rekomendatsii. Menopauza i klimaktericheskoe sostoianie u zhenshchiny [117_2]. 2024. Available at: https://cr.minzdrav.gov.ru/archive. Accessed: 20.08.2024 (in Russian)].
  22. Peker H, Gursoy A. Relationship between genitourinary syndrome of menopause and 3D high-frequency endovaginal ultrasound measurement of vaginal wall thickness. J Sex Med. 2021;18(7):1230-5. doi: 10.1016/j.jsxm.2021.05.004
  23. Warinsiriruk P, Tantitham C, Cherdshewasart W, et al. Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause. Maturitas. 2022;161:4-10. doi: 10.1016/j.maturitas.2022.01.005
  24. Sirotina LZ, Potapov AL, Loginova MM, et al. Criteria for vaginal atrophic changes in genitourinary syndrome of menopause using optical coherence tomography. Sovremennye tehnologii v medicine. 2025;17(2):24-33. doi: 10.17691/stm2025.17.2.03
  25. Miao Y, Sudol NT, Li Y, et al. Optical coherence tomography evaluation of vaginal epithelial thickness during CO2 laser treatment: a pilot study. J Biophotonics. 2022;15(11):e202200052. doi: 10.1002/jbio.202200052
  26. Isaza PG. Use of growth factors for vulvo/vaginal bio-stimulation. Surg Technol Int. 2019;34:269-73.
  27. Galli V, Golia D'Auge T, DI Pierro F, et al. Safety and efficacy of a class II medical device based on highly purified and standardized plant extracts in the management of post-menopausal patients with vulvar and vaginal atrophy: a single-center prospective observational study. Minerva Obstet Gynecol. 2024;76(4):343-52. doi: 10.23736/S2724-606X.23.05409-X
  28. Sanchez-Prieto M, Mendoza N, Chedraui P, et al. An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman. Gynecol Endocrinol. 2025;41(1):2500480. doi: 10.1080/09513590.2025.2500480
  29. Мальцева Л.И., Гафарова Е.А. Альтернативная терапия симптомов генитоуринарного менопаузального синдрома у женщин. Вопросы практической кольпоскопии. Генитальные инфекции. 2023;(1):24-30 [Maltseva LI, Gafarova EA. Alternative therapy of symptoms of genitourinary menopausal syndrome in women. Voprosy prakticheskoi kolposkopii. Genitalnye infektsii. 2023;(1):24-30 (in Russian)]. doi: 10.46393/27826392_2023_1_24
  30. Ермакова Е.И., Сметник А.А. Опыт клинического применения негормонального вагинального крема для лечения генитоуринарного менопаузального синдрома/вульвовагинальной атрофии у пациенток с эстрогензависимыми онкологическими заболеваниями в анамнезе. Акушерство и гинекология. 2023;8:175-84 [Ermakova EI, Smetnik AA. Opyt klinicheskogo primeneniia negormonalnogo vaginalnogo krema dlia lecheniia genitourinarnogo menopauzalnogo sindroma/vulvovaginalnoi atrofii u patsientok s estrogenzavisimymi onkologicheskimi zabolevaniiami v anamneze. Akusherstvo i Ginekologiia. 2023;8:175-84 (in Russian)]. DOI:10.18565/ aig.2023.192
  31. Доброхотова Ю.Э., Ильина И.Ю., Венедиктова М.Г., и др. Локальная негормональная терапия больных с генитоуринарным менопаузальным синдромом. Российский вестник акушера-гинеколога. 2018;18(3):88-94 [Dobrokhotova YuE, Ilyina IYu, Venediktova MG. Local nonhormonal therapy in patients with genitourinary menopausal syndrome. Russ Bull Obstet Gynecol. 2018;18(3):88-94 (in Russian)]. doi: 10.17116/rosakush201818388-94

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).